EGFR and non-small cell lung carcinoma: In a phase I, open-label, dose-escalation, and dose-expansion study (CHRYSALIS), Park et al. [29] enrolled eligible post-platinum EGFR Exon20ins NSCLC patients and treated them with the recommended dose of 1050 mg of amivantamab (every week for 4 weeks, and then every 2 weeks).